Taysha Gene Therapies Earnings
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Nov 3, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.14
Taysha Gene Therapies earnings summary
Taysha Gene Therapies is scheduled to report Sep/2026 earnings on Nov 3, 2026, with analysts expecting EPS of $-0.14. In its most recent report on Aug 11, 2026 (Q2 2026), TSHA posted EPS of $-0.13. Revenue for the quarter was $0.
Across the last 16 reports, TSHA shares moved an average of 8.8% (in either direction) in the first trading session after results, rising 11 times and falling 5 times.
Summary generated from market data by MetaCap's automated system. Methodology
TSHA earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 11, 2026 | — | $-0.13 | — | +2.4% |
| May 6, 2026 | — | $-0.12 | — | -12.5% |
| Mar 19, 2026 | — | $-0.08 | — | -7.5% |
| Nov 4, 2025 | — | $-0.09 | — | +7.8% |
| Aug 12, 2025 | — | $-0.09 | — | +2.0% |
| May 15, 2025 | — | $-0.08 | — | +1.9% |
| Feb 26, 2025 | — | $-0.07 | — | +9.4% |
| Nov 13, 2024 | — | $-0.10 | — | +19.9% |
| Aug 12, 2024 | — | $-0.09 | — | -2.2% |
| May 14, 2024 | — | $-0.10 | — | +4.9% |
| Mar 19, 2024 | — | $0.63 | — | -11.7% |
| Nov 14, 2023 | — | $-0.93 | — | +11.2% |
| Aug 14, 2023 | — | $-0.38 | — | +15.6% |
| May 11, 2023 | — | $-0.28 | — | +10.3% |
| Mar 28, 2023 | — | $-0.96 | — | -16.0% |
| Nov 8, 2022 | — | $-0.65 | — | +5.5% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.